Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020
July 13 2020 - 6:10PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, will report second fiscal quarter
2020 financial results after market close on Thursday, July 30,
2020.
Following the release of results, Douglas Bryant, president and
chief executive officer, and Randy Steward, chief financial
officer, will host an investment community conference call
beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to
discuss the results and answer questions. During the conference
call, the company will also discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
Investors may either join the live call by telephone, or via
webcast:
- To participate in the live call by telephone from the U.S.,
dial 833-968-2118, or from outside the U.S., dial 778-560-2849, and
either request the “Quidel Q2 2020 Earnings Call” when prompted by
the conference call operator, or dial conference ID 336-5909.
- To join the live webcast, participants may click the following
link directly:
https://event.on24.com/wcc/r/2399366/554769F2DE954BE74E6A85BD876C70DF,
or access the event via the Investor Relations section of the
Quidel website (http://ir.quidel.com).
The website replay will be available for 1 year. The telephone
replay will be available for 14 days beginning at 8:00 p.m. Eastern
Time (5:00 p.m. Pacific Time) on July 30th, 2020 by dialing
800-585-8367 from the U.S., or by dialing 416-621-4642 for
international callers, and entering pass code 336-5909.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, COVID-19, influenza,
respiratory syncytial virus, Strep A, lyme, herpes, pregnancy,
thyroid disease and fecal occult blood. Quidel's Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s
research and development engine is also developing a continuum of
diagnostic solutions from advanced immunoassay to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio,
and to explore exciting employment opportunities, visit
quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200713005678/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931 Media and Investors Contact: Quidel
Corporation Ruben Argueta (858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2023 to Apr 2024